Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Valuing Drugs In The US: How We're Doing And What's Ahead

Jan 23 2018

• By Cathy Kelly

Dollar sign made with drug pills

Related Content

Open-Source Rx Value Model Designed To Encourage 'More Productive' Discussions

Jan 23 2018

Patients’ View Of Drug Value Is Focus Of Avalere/FasterCures Framework

Dec 02 2016

Is ICER Too NICE? A Comparison Of Drug Assessments Programs

Dec 23 2016

ICER Expands Drug Value Comparison Program

Jul 21 2015

ASCO Cancer Drug Valuation Tool Will Incorporate Patient Preferences

May 31 2016

Cancer Drug Comparisons Released By NCCN, Include Affordability

Oct 16 2015

ICER Eyes Gene Therapy: Category-wide Policy In Works As Spark Moves To Approval

Jul 05 2017

Large Employer Co-Op Using PBMs In Drug Coverage Initiative, For Now

Mar 09 2017

ICER Views CAR-T Therapies Kymriah, Yescarta As Cost Effective

Dec 22 2017

Related Companies

Memorial Sloan Kettering Cancer Center

Novartis AG

Kite Pharma, Inc.

Additional Topics

United States Health Technology Assessment Market Access Commercial Pricing Strategies Reimbursement BioPharmaceutical

More from Health Technology Assessment

More from Market Access

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window